Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Phase II of zanubrutinib + ixazomib/dex in newly diagnosed Waldenström macroglobulinemia finds 4.2% CR and 41.6% VGPR rates; overall, major and deep remission rates 100%, 95.8% and 45.8%; median PFS and OS 40 mos and not reached.”
Authors: Wenjie Xiong, Yuting Yan, Tingyu Wang, Lugui Qiu, Shuhua Yi et al.
More posts featuring Robert Orlowski.
